Welcome to our dedicated page for Celldex Therapeutics SEC filings (Ticker: CLDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech such as Celldex Therapeutics means untangling pages of trial data, FDA risk factors, and stock-based compensation tables. If you have ever opened Celldex’s latest 10-K only to hunt for cash-runway disclosures or barzolvolimab trial timelines, you know the challenge.
Stock Titan solves it. Our AI reads every Celldex Therapeutics quarterly earnings report 10-Q filing, annual report 10-K, and 8-K material event the moment it hits EDGAR, then translates the biotech jargon into plain English summaries, key metrics, and trend charts you can grasp in minutes. Want to monitor Celldex Therapeutics insider trading Form 4 transactions? Real-time alerts surface executive stock moves so you can gauge insider conviction without scanning multiple PDFs.
- 10-K & 10-Q—cash burn, R&D spend by program, pivotal trial milestones, all explained simply.
- Form 4—insider buys or sells, including Celldex Therapeutics executive stock transactions Form 4, delivered as they post.
- 8-K—material disclosures like breakthrough-therapy designations or financing deals, with context on why they matter.
- Proxy statements—clear breakdowns of Celldex Therapeutics proxy statement executive compensation for benchmarking management incentives.
Whether you are asking “How do I read Celldex Therapeutics’ 10-K?” or comparing Form 4 patterns ahead of trial data, Stock Titan’s AI-powered analysis keeps you ahead. Save hours, spot risks early, and make better calls on this mast-cell biology leader—without wading through every page.
Form 144 filing overview: Donaldson Company, Inc. (DCI) has submitted a Form 144 indicating the proposed sale of up to 45,808 common shares through Morgan Stanley Smith Barney LLC on the NYSE. The filing lists an aggregate market value of $3.29 million for the shares and an approximate sale date of 07/10/2025. The shares were acquired the same day via cash exercise of employee stock options.
Insider selling activity: The notice also discloses that Tod Carpenter sold 14,192 shares during the prior three months (sales on 07/08/2025 and 07/09/2025) for total gross proceeds of $1.01 million. When combined with the new notice, Carpenter could dispose of up to 60,000+ shares within a short window.
Ownership context: With 116,519,946 shares outstanding, the proposed 45,808-share sale represents approximately 0.04 % of total shares, suggesting limited dilution risk but providing a datapoint on insider sentiment.
Regulatory notes: Under Rule 144, the filer certifies that no undisclosed material adverse information exists and that volume and manner-of-sale limits are observed. The broker listed will conduct the sale on the open market.
FAQ
What is the current stock price of Celldex Therapeutics (CLDX)?
What is the market cap of Celldex Therapeutics (CLDX)?
What does Celldex Therapeutics specialize in?
What is barzolvolimab, and what conditions does it target?
How does Celldex differentiate itself from competitors?
What are the key challenges Celldex faces?
What is CDX-622, and what makes it unique?
What is Celldex’s approach to chronic urticarias?
What is the significance of mast cell biology in Celldex’s pipeline?
What are Celldex’s long-term growth opportunities?
